| Home | E-Submission | Sitemap | Editorial Office
Korean J Hepatol > Volume 13(3); 2007 > Article
The Korean Journal of Hepatology 2007;13(3): 349-362.
doi: https://doi.org/10.3350/kjhep.2007.13.3.349
Effect of Initial Virologic Response to Adefovir on the Development of Resistance to Adefovir in Lamivudine-resistant Chronic Hepatitis B
In Hee Kim , Seong Hun Kim , Hyun Chul Kim , Kyoung Deok Shin , Sang Wook Kim , Seong Ok Lee , Soo Teik Lee , Dae Ghon Kim
Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea

Adefovir dipivoxil (ADV) resistance in patients with lamivudine-resistant chronic hepatitis B is not well understood. This study examined the initial virologic response (IVR) to ADV, the rate of ADV resistance and the factors associated with ADV resistance.
Eighty one lamivudine-resistant HBeAg-positive patients were enrolled in this study. IVR was defined as HBV DNA < 4 log10 copies/mL after 6 months of therapy.
IVR was observed in 37/81(45.7%) patients and it was associated with higher pretreatment ALT (P=0.002), and low pretreatment HBV DNA level (P=0.015). The HBV DNA levels were significantly higher in the non-IVR patients than the IVR patients at 12, 18 and 24 months (4.73 vs 2.59, 4.53 vs 2.31, 4.39 vs 2.40 log10 copies/mL, respectively; P<0.01). During the follow-up period, 17(21.0%) patients showed phenotypic resistance to ADV and 9 (11.1%) patients had ADV-resistant mutations. The cumulative probabilities of the phenotypic resistance to ADV at 12 and 24 months were 8.7% and 32.5%, respectively. The cumulative probabilities of the genotypic resistance to ADV at 12 and 24 months were 0% and 14.6%, respectively. Resistance to ADV was associated with a higher pretreatment HBV DNA (P=0.019), and non-IVR (P<0.001).
The cumulative probabilities of the phenotypic and genotypic resistance to ADV at 24 months were 32.5% and 14.6%. The high pretreatment HBV DNA and non-IVR (HBV DNA ≥ 4 log10 copies/mL after 6 months of therapy) were associated with ADV resistance. (Korean J Hepatol 2007;13: 349-362)
KeyWords: Adefovir; Drug resistance; Hepatitis B, chronic; Lamivudine
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
Related articles
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients  2011 December;17(4)
Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients  2015 June;21(2)
Efficacy and predictors of the virologic response to entecavir therapy in nucleoside naive patients with chronic hepatitis B  2010 March;16(1)
Predictors for virologic response in management of chronic hepatitis B  2010 March;16(1)
Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, Lamivudine-resistant chronic hepatitis B patients  2009 March;15(1)
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association for the Study of the Liver. All rights reserved.